MK-677 as a 'gains pill': what the evidence actually shows

What did @drmikeisraetel actually say?

Dr. Mike Israetel claims that MK-677 can produce "three to five pounds of muscle" over 12 weeks, that you might keep some of that after stopping, and that running two cycles per year could mean "an extra four to six pounds a year." He also made an unusually candid admission: he called it "low-key poison" before pivoting to a pragmatic "knowing your risks" framing. That tension between "here are the gains" and "this stuff is risky" is the whole ballgame here, and it deserves unpacking rather than a simple thumbs up or down.

To his credit, he did not tell viewers to use it. He framed it as a personal risk calculation. That is a more honest approach than most MK-677 content on this platform, which tends to skip the poison part entirely.

Does the science back this up?

The 3-5 pound muscle gain figure is in the right neighborhood but requires serious caveats about what the studies actually measured and who the subjects were. Most MK-677 trials are not 12-week hypertrophy studies in resistance-trained athletes.

The most-cited human trial (Svensson et al., 1998, Journal of Clinical Endocrinology and Metabolism) found increases in lean body mass in healthy older adults, but lean body mass is not the same as muscle. It includes water and glycogen. A later study by Nass et al. (2008, Annals of Internal Medicine) in older adults with hip fractures showed improved lean mass and function, but again, not a gym population. The data in well-trained younger lifters is essentially nonexistent in peer-reviewed literature. Israetel is extrapolating from clinical and elderly populations to advanced athletes, which is a significant leap. The gains may be real, but the exact numbers are not established for his stated audience.

What did they get wrong (or right)?

He got the general mechanism right. MK-677 is a ghrelin mimetic that stimulates growth hormone secretion, and yes, elevated GH and IGF-1 can support muscle protein synthesis. That part is not controversial.

Where it gets shakier: the framing that health impacts are "very controlled" and "moderate to mild" is doing a lot of heavy lifting. MK-677 is associated with increased fasting glucose and insulin resistance (Murphy et al., 1998, Journal of Clinical Endocrinology and Metabolism), water retention, and in some users significant edema. There is also a documented increase in appetite that can be substantial. For people with pre-diabetes, insulin sensitivity issues, or cardiovascular risk factors, "mild impact" is not the right description. The "low-key poison" quip lands closer to the truth than the "moderate impact" framing does.

He also did not mention that MK-677 is not approved by the FDA for any indication, is not a peptide in the strict pharmacological sense but a small molecule, and has been banned by WADA since 2008.

What should you actually know?

MK-677 sits in a genuinely complicated space. It is not a synthetic anabolic steroid, but it is not a harmless supplement either. The honest version of the risk profile looks like this: chronic elevation of GH and IGF-1 carries theoretical long-term risks including promotion of existing neoplasms, though causation in humans at these doses is not established. Short-term, the metabolic side effects are real and measurable.

If you are considering MK-677 through any channel, including a telehealth platform, the conversation should start with baseline bloodwork covering fasting glucose, HbA1c, and IGF-1 levels, and those markers should be tracked during use. Anyone with a personal or family history of cancer, diabetes, or acromegaly-related conditions should approach this with significant caution and direct physician involvement, not a TikTok comment section.

The gains Israetel describes are plausible but not proven in the specific population he is addressing. The risks he briefly names are real and in some cases underplayed.